Profile data is unavailable for this security.
About the company
Hangzhou TianMuShan Pharmaceutical Enterprise Co., Ltd is a China based company principally engaged in the research and development, production and sales of pharmaceuticals and related health products. The Company is mainly engaged in the manufacture of chemical drug substances, processing of Chinese herbal pieces as well as the manufacture of traditional Chinese medicine preparation and Western medicine. The Company's main products are bright eye drops, FufangXianzhuliYe, amoxicillin and clavulanate potassium tablets, Hechedazao Jiaonang, Liu Wei Di Huang oral liquid, menthol, and peppermint oil. The Company mainly operates its business in the domestic market.
- Revenue in CNY (TTM)160.35m
- Net income in CNY-14.51m
- Incorporated1993
- Employees380.00
- LocationHangzhou TianMuShan Pharmaceutical Enterprise Co LtdRoom 1803-1804, Boya Times Center, ShixiHANGZHOU 311200ChinaCHN
- Phone+86 57 163722229
- Fax+86 57 163715400
- Websitehttp://www.hztmyy.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AFT Pharmaceuticals Ltd | 826.37m | 66.01m | 1.10bn | 110.00 | 16.66 | 2.96 | 14.76 | 1.33 | 0.1489 | 0.1489 | 1.86 | 0.8372 | 1.25 | 2.34 | 4.30 | 1,776,464.00 | 9.96 | 11.44 | 13.72 | 16.49 | 45.17 | 45.65 | 7.99 | 9.50 | 1.23 | 6.69 | 0.2683 | 4.43 | 24.75 | 18.08 | 46.51 | -- | 22.42 | -- |
| Hangzhou Tianmushan Phrmtcl ntrprs C Ltd | 160.35m | -14.51m | 1.14bn | 380.00 | -- | 34.23 | -- | 7.14 | -0.1192 | -0.1192 | 1.32 | 0.2746 | 0.4537 | 2.29 | 3.43 | 421,978.40 | -4.39 | -6.93 | -22.04 | -18.92 | 36.69 | 33.95 | -9.69 | -16.42 | 0.4497 | -1.95 | 0.6938 | -- | 11.82 | -19.42 | 43.35 | -- | -24.89 | -- |
| SinoMab Bioscience Ltd | 2.03m | -199.75m | 1.15bn | 214.00 | -- | 4.14 | -- | 565.40 | -0.2064 | -0.2064 | 0.0021 | 0.2732 | 0.0023 | -- | -- | 10,148.60 | -22.83 | -24.62 | -29.11 | -27.72 | 26.80 | -- | -9,853.75 | -4,451.74 | -- | -81.79 | 0.6339 | -- | -- | -- | 14.45 | -- | 106.81 | -- |
| Fuso Pharmaceutical Industries Ltd | 2.67bn | 101.55m | 1.15bn | 1.31k | 10.23 | 0.5935 | 5.56 | 0.4311 | 257.39 | 257.39 | 6,774.96 | 4,436.49 | 0.7581 | 3.07 | 2.33 | 44,163,730.00 | 2.89 | 1.91 | 4.97 | 3.09 | 26.58 | 26.92 | 3.81 | 2.69 | 0.9406 | 50.75 | 0.267 | 41.10 | 8.61 | 3.76 | -14.21 | 9.02 | 9.13 | -2.64 |
| Remus Pharmaceuticals Ltd | 181.88m | 18.43m | 1.16bn | 48.00 | 61.61 | 15.61 | 50.44 | 6.38 | 37.34 | 37.34 | 374.91 | 147.42 | 1.46 | 7.61 | 3.56 | 44,270,750.00 | 17.80 | -- | 44.48 | -- | 22.67 | -- | 12.22 | -- | 1.12 | 55.56 | 0.0997 | -- | 371.94 | -- | 153.29 | -- | -- | -- |
Data as of Nov 15 2024. Currency figures normalised to Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
